Skip to main content

Market Overview

Analysts Weigh In On Amended Bluebird Bio/Celgene Deal

Share:

Bluebird bio Inc (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG) announced a restructuring of its CAR-T collaboration this week. Under the amended terms of the deal, the collaboration will focus on CAR-T cells that target the B-cell maturation antigen (BCMA). Celgene will also provide $25 million in funding to bluebird.

What does Wall Street think of the new deal? Here’s a breakdown of what four firms had to say following the announcement.

Wedbush

Wedbush remains bullish on bluebird following the announcement, and expects the anti-BCMA collaboration to focus on multiple myeloma (MM).

“BCMA is primarily expressed by plasma cells, with near universal expression in MM cells. Critically, with regards to preventing off-target toxicities, BCMA does not appear to be expressed in essential normal tissues,” analysts explain.

Wedbush maintains its Outperform rating and $222 price target for bluebird.

Bank of America

Bank of America analysts seem puzzled by the anti-BCMA amendment, but maintain high hopes for bluebird.

“While it is not clear to us why the amendment took place, we remind investors that LentiGlobin is the main value driver, and we remain bullish on the prospect of the beta-thalassemia and sickle cell programs,” analysts add.

JP Morgan

JP Morgan analysts say that the amendment “has no impact on our thesis” when it comes to bluebird. JP Morgan has an Overweight rating on the stock and sees any weakness in upcoming days as a buying opportunity.

Roth

According to Roth analysts, “The change may be a reflection of the challenges that need to be addressed with CARTs, but it may also be a sign of bluebird’s growing confidence in its in-house expertise.” Roth echoes JP Morgan’s belief that any weakness in bluebird’s stock should be considered a buying opportunity.

Latest Ratings for BLUE

DateFirmActionFromTo
Apr 2021Morgan StanleyMaintainsEqual-Weight
Mar 2021SVB LeerinkMaintainsOutperform
Mar 2021MizuhoUpgradesNeutralBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

 

Related Articles (CELG + BLUE)

View Comments and Join the Discussion!

Posted-In: Bank of AmericaAnalyst Color Biotech Price Target Reiteration Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com